IDF EUROPE GA MEETING MUNICH,2005 SURVEY ON DIABETES CARE IN EIGHT CENTRAL EASTERN EUROPEAN COUNTRIES (THE DEPAC STUDY)

Survey of diabetes care in eight new EU accessing countries Planned and organized by the Diabetes Experts’ Panel from Accessing Countries (DEPAC) established in May 2004 PROTOCOL A multi-centre, randomised, non-interventional survey assessing metabolic control, short- and long term complications, and diabetes care of patients in 8 EU accessing countries

Timelines of the survey (Critical milestones) Preparations phase Final protocol approved 22 Oct 2004 Translation of protocol into local languages 5 Nov Investigators’ meetings in countries 19 Nov–17 Dec Operations phase Collection of data started 03 Jan 2005 Collection of data completed 28 Feb Analysis phase Statistical analysis complete 20 March Integrated survey report complete (abstract to EASD) 28 March

Number of patients (planned:10 000; collected:11 085) EST200 HU 1800 LAT300 CZ 2000 LIT300 SLO 300 SK 1100 PL 4000

CLASSIFICATION Type 1 DM: % Type 2 DM: % Other Types of DM: %

AGE AND DIABETES DURATION Mean age (years): Type 1 men:37,07 Type 2: 61,08 women: 36,70 63,17 Diabetes duration (years): Type 1 men: 13,21 Type 2 : 9,61 women: 14,37 10,68

INSULIN TREATMENT Human insulins: Type 1 DM: 70.10% Type 2 DM: 40.50% Analog insulins: Type 1 : 49.03% Type 2 : 10.82%

ORAL TREATMENT Metformin Sulphonyloureas Type 2 DM: 50.70% 39.0% Acarbose Oral + Insulin Type 2 : 10.0% 14.20%

Results: metabolic control and lipids Poor metabolic control (HbA1c > 8%) Type 1 DM: 49.10% Type 2 DM: 36.77% Dyslipidemia (high serum lipids) Type 1 : 29.03% Type 2 : 66.82%

Results: microvascular complications Retinopathy Type 1 : 41.30% Type 2 : 32.34% Nephropathy Type 1 : 28.46% Type 2 : 25.02% Neuropathy Type 1 : 31.79% Type 2 : 30.22%

Results: cardiovascular complications Hypertension Type 1 : 30.52% Type 2 : 79.49% Cardiovascular disease Type 1 : 8.58% Type 2 : 43.34%

SURVEY ANALYSIS The only differences in diabetic complications between men and women which reached statistically significant levels were: hypertension (P<0.01), myocardial infarction (P<0.001), peripheral arterial disease (P<0.001) and diabetic foot ulcer (P<0.001)

CONCLUSIONS The results should be a platform for further goals on country and EU levels: -highlighting the costs and benefits from diabetes treatment, -creating ways of health promotion and health monitoring, - increasing patient empowerment through education, - discussion about the status of National Diabetes Programmes in each countries.